Advertisement
Advertisement
U.S. markets open in 7 hours 54 minutes
S&P Futures
4,131.25 -16.50 (-0.40%) Dow Futures
33,864.00 -98.00 (-0.29%) Nasdaq Futures
12,563.75 -60.25 (-0.48%) Russell 2000 Futures
1,983.40 -10.10 (-0.51%) Crude Oil
73.43 +0.04 (+0.05%) Gold
1,891.30 +14.70 (+0.78%)
ARYA Sciences Acquisition Corp IV (ARYD)
NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Follow
At close: 02:25PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 10.16 |
| Open | 10.17 |
| Bid | 0.00 x 28000 |
| Ask | 0.00 x 800 |
| Day's Range | 10.17 - 10.17 |
| 52 Week Range | 9.70 - 10.17 |
| Volume | |
| Avg. Volume | 100,336 |
| Market Cap | 195.127M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 113.00 |
| EPS (TTM) | 0.09 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-46% Est. Return
Subscribe to Yahoo Finance Plus to view Fair Value for ARYD
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- GlobeNewswire
ARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus’ Gene Therapy Business Due to Market Conditions
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp IV (NASDAQ: ARYD) (“ARYA IV”), a publicly traded special purpose acquisition company sponsored by Perceptive Advisors announced today that, due to existing market conditions, it has mutually agreed with Amicus Therapeutics, Inc. (Nasdaq: FOLD) (“Amicus”) to terminate their previously announced Business Combination Agreement (the “Business Combination Agreement”), effective immediately. “While this is not the outcome we ha
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.
